Apelin-13 in blood pressure regulation and cardiovascular disease

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 5, 2016, Pages 396-403

  Yamaleyeva, Liliya M ^a   Shaltout, Hossam A ^a   Varagic, Jasmina ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

apelin; APJ; blood pressure; heart disease

Indexed keywords

ANGIOPOIETIN RECEPTOR; APELIN; APELIN 13; APELIN RECEPTOR; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSITOL TRISPHOSPHATE; MICRORNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN KINASE; NITRIC OXIDE; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; PYROGLUTAMATE APELIN 13; PYROGLUTAMIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; SIRTUIN 3; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; SPHINGOSINE KINASE 1; STROMAL CELL DERIVED FACTOR 1ALPHA; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTIHYPERTENSIVE AGENT; APELIN-13 PEPTIDE; SIGNAL PEPTIDE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR GENE THERAPY; CORONARY ARTERY BLOOD FLOW; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; GENE AMPLIFICATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; INOTROPISM; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; ROSTRAL VENTROLATERAL MEDULLA; SARCOPLASMIC RETICULUM; SOLITARY TRACT NUCLEUS; VASCULAR RESISTANCE; VASODILATATION; BLOOD PRESSURE; DRUG EFFECTS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL ISCHEMIA;

EID: 84973514409     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000241     Document Type: Review

References (68)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
2. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-476
3. O'Carroll AM, Lolait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol 2013; 219: R13-R35
4. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198-211
5. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84: 1162-1172
6. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74: 34-41
7. Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem 2013; 442: 1-9
8. Shin K, Pandey A, Liu XQ, et al. Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio 2013; 3: 328-333
9. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843
10. Sato T, Suzuki T, Watanabe H, et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 2013; 123: 5203-5211
11. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009; 54: 598-604
12. Iturrioz X, Gerbier R, Leroux V, et al. By interacting with the C-Terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization. J Biol Chem 2010; 285: 3262737
13. Azizi M, Iturrioz X, Blanchard A, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol 2008; 19: 1015-1024
14. Yamaleyeva LM, Chappell MC, Brosnihan KB, et al. Downregulation of apelin in the human placental chorionic villi from preeclamptic pregnancies. Am J Physiol Endocrinol Metab 2015; 309: E852-E860
15. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011; 29: 971-979
16. Papadopoulos DP, Makris T, Perrea D, et al. Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. J Clin Hypertens (Greenwich) 2014; 16: 198-201
17. Liakos CI, Sanidas EA, Perrea DN, et al. Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure. Am J Hypertens 2016; 29: 549-552
18. Horbal SR, Seffens W, Davis AR, et al. Associations of apelin, visfatin, and urinary 8-isoprostane with severe hypertension in African Americans: the MHGRID Study. Am J Hypertens 2016; doi: 10.1093/ajh/hpw007. [Epub ahead of print]
19. Li WW, Niu WQ, Zhang Y, et al. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens 2009; 27: 1194-1201
20. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343-3354
21. Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146: 231-236
22. Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010; 121: 1818-1827
23. Barnes GD, Alam S, Carter G, et al. Sustained cardiovascular actions of APJ agonism during renin angiotensin system activation and in patients with heart failure. Circ Heart Fail 2013; 6: 482-491
24. Najafipour H, Soltani HA, Nekooian AA, Esmaeili-Mahani S. Apelin receptor expression in ischemic and non ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept 2012; 178: 43-50
25. Akcilar R, Turgut S, Caner V, et al. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens 2013; 35: 550-557
26. Brame AL, Maguire JJ, Yang P, et al. Design, characterization, and first-inhuman study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 2015; 65: 834-840
27. Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008; 52: 908-913
28. Han X, Zhang DL, Yin DX, et al. Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can J Physiol Pharmacol 2013; 91: 708-714
29. Yamaleyeva LM, Brosnihan KB, McGee C, et al. Systemic administration of (Pyr1)-Apelin-13 at late pregnancy reduces blood pressure, proteinuria, and improves autonomic function in preeclamptic rats. American Heart Association High Blood Pressure Research Scientific Sessions E126. 2015
30. Siddiquee K, Hampton J, McAnally D, et al. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2013; 168: 1104-1117
31. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013; 19: 74-82
32. Mitra A, Katovich MJ, Mecca A, Rowland NE. Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. Physiol Behav 2006; 89: 221-225
33. Seyedabadi M, Goodchild AK, Pilowsky PM. Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton Neurosci 2002; 101: 32-38
34. Zhang CR, Xia CM, Jiang MY, et al. Repeated electroacupuncture attenuating of apelin expression and function in the rostral ventrolateral medulla in stressinduced hypertensive rats. Brain Res Bull 2013; 97: 53-62
35. Cudnoch-Jedrzejewska A, Gomolka R, Szczepanska-Sadowska E, et al. Highfat diet and chronic stress reduce central pressor and tachycardic effects of apelin in Sprague-Dawley rats. Clin Exp Pharmacol Physiol 2015; 42: 52-62
36. Gomolka RS, Cudnoch-Jedrzejewska A, Czarzasta K, Szczepanska-Sadowska E. Reduction of pressor response to stress by centrally acting apelin in spontaneously hypertensive rats. J Basic Clin Physiol Pharmacol 2015; 26: 233-236
37. Kagiyama S, Fukuhara M, Matsumura K, et al. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005; 125: 55-59
38. Zhou LM, Shi Z, Gao J, Han Y, et al. Angiotensin-(1-7) and angiotension II in the rostral ventrolateral medulla modulate the cardiac sympathetic afferent reflex and sympathetic activity in rats. Pflugers Arch 2010; 459: 681-688
39. Perjes A, Skoumal R, Tenhunen O, et al. Apelin increases cardiac contractility via protein kinase Cepsilon and extracellular signal-regulated kinase-dependent mechanisms. PLoS One 2014; 9: e93473
40. Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91: 434-440
41. Wang C, Du JF, Wu F, Wang HC. Apelin decreases the SR Ca2θ content but enhances the amplitude of [Ca2θ]i transient and contractions during twitches in isolated rat cardiac myocytes. Am J Physiol Heart Circ Physiol 2008; 294: H2540-H2546
42. Rastaldo R, Cappello S, Folino A, Losano G. Effect of apelin-Apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool?. Antioxid Redox Signal 2011; 14: 909-922
43. Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007; 357: 889-895
44. Foldes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003; 308: 480-485
45. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin IIangiotensin type 1 receptor system. J Mol Cell Cardiol 2006; 41: 798-806
46. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75: 1882-1892
47. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110 (Suppl II): II-187-II-193
48. Pang H, Han B, Yu T, Zong Z. Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure. Int J Mol Med 2014; 34: 756-764
49. Atluri P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007; 12: 127-138
50. Zeng XJ, Zhang LK, Wang HX, et al. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009; 30: 1144-1152
51. Liu Q, Hu T, He L, Huang X, et al. Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun 2015; 6: 6020
52. Grzywocz P, Mizia-Stec K, Wybraniec M, Chudek J. Adipokines and endothelial dysfunction in acute myocardial infarction and the risk of recurrent cardiovascular events. J Cardiovasc Med (Hagerstown) 2015; 16: 37-44
53. Weir RA, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 2009; 11: 551-558
54. Azizi Y, Faghihi M, Imani A, et al. Postinfarct treatment with [Pyr1]-Apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013; 46: 76-82
55. Azizi Y, Faghihi M, Imani A, et al. Postinfarct treatment with [Pyr(1)]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats. Eur J Pharmacol 2015; 761: 101-108
56. Hou X, Zeng H, He X, Chen JX. Sirt3 is essential for apelin-induced angiogenesis in postmyocardial infarction of diabetes. J Cell Mol Med 2015; 19: 53-61
57. Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol 2012; 303: H605-H618
58. Li L, Zeng H, Hou X, et al. Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One 2013; 8: e71041
59. Zhang NK, Cao Y, Zhu ZM, et al. Activation of endogenous cardiac stem cells by apelin-13 in infarcted rat heart. Cell Transplant 2016; doi: 10.3727/096368916X691123. [Epub ahead of print]
60. Tao J, Zhu W, Li Y, et al. Apelin-13 protects the heart against ischemiareperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol 2011; 301: H1471-H1486
61. SmithCC, MocanuMM, BowenJ, et al. Temporal changes inmyocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. Cardiovasc Drugs Ther 2007; 21: 409-414
62. Koguchi W, Kobayashi N, Takeshima H, et al. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012; 76: 137-144
63. Pchejetski D, Foussal C, Alfarano C, et al Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1Eur Heart J 2012; 33:2360-2369
64. Murza A, Besserer-Offroy E, Cote J, et al. C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action. J Med Chem 2015; 58: 2431-2440
65. Serpooshan V, Sivanesan S, Huang X, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials 2015; 37: 289-298
66. Zeng H, He X, Hou X, et al. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol 2014; 306: H585-H597
67. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell 2013; 27: 672-680
68. Perjes A, Kilpio T, Ulvila J, et al. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol 2016; 111: 2